PAYER POLICY CHANGES

C9076 Insurance Policy Changes

HCPCS C9076 is officially defined as "Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose." HCPCS C9076 is referenced in 2 tracked payer policy changes from Premera Blue Cross. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS C9076 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Watch C9076

Get one email when a payer policy names C9076, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

See every payer rule for C9076

Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for C9076 in one place.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.